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objective of this pharmacoeconomic analysis is to access the cost-
effectiveness of capecitabine compared to 5-FU/LV in the adju-
vant setting in Taiwan from the payer’s [Bureau of National
Health Insurance (BNHI)] perspective. METHODS: A state-
transition economic model was developed to estimate incremen-
tal cost impact and the effectiveness in terms of quality-adjusted
life months (QALMs). Clinical outcomes and medical resource
utilization were collected during the phase III X-ACT study.
Direct medical costs associated with chemotherapy drugs, physi-
cian consultations, and adverse events (AEs) management were
based on Taiwan’s National Health Insurance fee schedule. Intra-
venous chemotherapy administration costs and post-treatment
costs were estimated from an expert panel survey conducted
among 12 colorectal surgeons and medical oncologists. Health-
related utility scores were obtained from published literature.
Outcomes and future costs were discounted at 1.5% and 6%
respectively. Sensitivity analyses were performed on key model
parameters. RESULTS: Administration of capecitabine required
fewer physician visits per patient (7.4 versus 28.0 with 5-FU/LV).
Drug acquisition costs of capecitabine were higher than 5-FU/LV,
however, these cost increments were offset by the chemotherapy
administration cost of 5-FU/LV. In addition, more expensive
medications and longer hospitalization were needed to manage
5-FU/LV-related AEs. As a result, capecitabine demonstrated a
signiﬁcant overall cost savings of $104,546 NTD. Over a life-
time, the survival beneﬁt for capecitabine extends to 9 QALMs.
Capecitabine remained dominant under sensitivity testing. CON-
CLUSION: From a Taiwan BNHI perspective, this pharma-
coeconomic analysis showed that the use of capecitabine in
adjuvant treatment of colon cancer would not only save direct
medical costs but also improve health outcomes compared to 
5-FU/LV.
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60-MONTH DATA FROM IRIS USED TO UPDATE ESTIMATES
OF SURVIVAL AND COST-EFFECTIVENESS OF FIRST-LINE
IMATINIB IN PATIENTS WITH CHRONIC PHASE CHRONIC
MYELOID LEUKEMIA
Reed SD,Anstrom KJ, Li Y, Schulman KA
Duke Clinical Research Institute, Durham, NC, USA
OBJECTIVES: With 60 months of follow-up data now available
from the IRIS trial, we updated our previous cost-effectiveness
analysis of ﬁrst-line imatinib versus interferon-á plus cytarabine
(IFN) in newly diagnosed patients with chronic myeloid
leukemia in the chronic phase that was originally based on a
median of 19 months of follow-up. METHODS: We used the
empirical 60-month data from IRIS for patients randomized to
imatinib to calibrate the survival curves generated with the cost-
effectiveness model. Due to the high rate of crossover among
patients randomized to IFN in IRIS, we relied on historical data
to model survival estimates for patients treated with IFN. We
updated costs to 2006 values and applied two sets of costs to
imatinib and IFN: average wholesale prices (AWP) and whole-
sale acquisition costs (WAC). RESULTS: Survival at 5 years for
patients randomized to imatinib was better than predicted with
our original model (89.4% vs. 83.2%). After model calibration,
we estimated remaining life expectancy for ﬁrst-line imatinib
patients to be 19.1 years, an increase of 3.8 years over the orig-
inal model. Remaining quality-adjusted life-years (QALYs) were
estimated at 15.2, an increase of 3.1 QALYs. Estimates for
patients randomized to IFN were maintained at 9.1 years and
6.3 QALYs. With AWPs, ICERs ranged from $40,300 to
$57,100 per QALY when applying less and more conservative
assumptions about the duration of ﬁrst- and second-line treat-
ment with imatinib and IFN. With WACs, ICERs ranged from
$33,500 to $46,100 per QALY. CONCLUSION: Although our
analysis revealed that our initial survival estimates were conser-
vative, the updated ICERs were relatively consistent with our
original estimate of $43,300 per QALY. Periodically updating
cost-effectiveness analyses should be a routine practice in cases
where ongoing survival data are collected. Even with 5 years of
data, most of the expected survival beneﬁt has yet to be observed.
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PSYCHOMETRIC VALIDATION OF A PATIENT SYMPTOM
ASSESSMENT-LUNG CANCER (PSALC) INSTRUMENT FOR
SMALL CELL LUNG CANCER (SCLC)
Chen L1, Duh M1,Antras L1, Neary MP2, O’Brien ME3
1Analysis Group, Inc, Boston, MA, USA, 2GlaxoSmithKline, Collegeville,
PA, USA, 3Royal Marsden Hospital, Sutton, UK
OBJECTIVES: The PSALC is an instrument that was developed
for use in patients with SCLC for assessment of nine symptoms
(i.e., shortness of breath, cough, chest pain, hemoptysis, appetite
loss, sleep interference, hoarseness, fatigue, interference with
daily activities) scored on a scale from 1 (not at all) to 4 (very
much), but it has not been formally validated. METHODS: A
retrospective psychometric validation was conducted using data
from a randomized multicenter trial in which 107 patients with
SCLC were treated with intravenous topotecan and 104 patients
with cyclophosphamide, doxorubicin, and vincristine. PSALC
was administered to patients at baseline and at each of the four
subsequent clinical visits at 3-week intervals. Factor analysis
(FA), internal consistency, construct validity, reliability, and
responsiveness were evaluated. RESULTS: Baseline FA (n = 137)
indicated that there was only one factor, so the PSALC total score
was used for validation. Weighted Cronbach’s alpha from all
visits was 0.74 showing an acceptable internal consistency. 
Construct validity was supported by the high correlation with
established measures, with lower baseline PSALC total scores
associated with better Eastern Cooperative Oncology Group
(ECOG) performance status (12.41, 18.24, and 20.33 for ECOG
score = 0, 1, and 2, respectively, p < 0.0001; regression slope esti-
mate = 3.84, p < 0.0001; n = 135). Reliability was supported by
an intraclass correlation coefﬁcient of 0.61, calculated using
PSALC total scores evaluated before any change in clinical
status, and a concordance correlation coefﬁcient of 0.72, calcu-
lated using PSALC total scores at baseline and before the ﬁrst
visit. The PSALC total score was responsive to tumor progres-
sion (responsiveness statistic = 0.64; n = 33). CONCLUSION: A
retrospective analysis suggests that the PSALC is a reliable, valid,
and responsive instrument for measuring SCLC symptoms. If
feasible in this population, a prospective validation study could
be used to further evaluate these ﬁndings.
PODIUM SESSION III: COST STUDIES
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EPOETIN ALFA AND DARBEPOETIN ALFA DOSING TRENDS
AND DRUG COSTS IN ELDERLY PRE-DIALYSIS CHRONIC
KIDNEY DISEASE PATIENTS
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OBJECTIVES: To evaluate trends in epoetin alfa (EPO) and 
darbepoetin alfa (DARB) dosing patterns and drug costs from
2005–2006 in elderly patients with pre-dialysis chronic kidney
disease (CKD) receiving care in nephrology clinics. METHODS:
A random panel of approximately 250 nephrologists was
requested to review the medical records of their two most
recently seen anemic pre-dialysis CKD patients who were receiv-
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ing an erythropoiesis-stimulating therapy (EST). Patients were
included in this analysis if they were >=65 years old and received
therapy between October 2005 and October 2006. Patient
demographics, comorbid conditions, baseline hemoglobin, CKD
status, EST dose, and frequency of administration were collected.
Drug cost was based on average weekly dose and September
2006 wholesale acquisition cost (EPO $12.17/1000 Units; DARB
$4.446/mcg). RESULTS: 862 patient charts were reviewed; 556
patients met eligibility criteria (EPO: 351; DARB: 205). Patient
demographics, comorbid conditions, baseline hemoglobin, and
CKD status were similar between groups. Weekly and extended
(>= every two weeks [>= Q2W]) dosing patterns were seen in
both groups (EPO: QW, 39%; >= Q2W, 61%; DARB: QW, 8%;
>= Q2W, 92%). The average weekly dose over the course of the
study (EPO: 10,719 units; DARB: 48 mcg) corresponded to a
dose ratio of 223 : 1 (Units EPO: mcg DARB) and weekly costs
of $130 for EPO and $213 for DARB. CONCLUSION: The
doses and 39% lower drug cost in the EPO group observed in
this study were similar to those published from earlier time
periods. The results reported here should be of assistance to clin-
icians and formulary decision makers in identifying current real-
world dosing and subsequent cost of treatment of these two
erythropoietic agents.
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OUTCOMES ASSOCIATED WITH THE USE OF
THIAZOLIDINEDIONES AMONG MEDICARE BENEFICIARIES
WITH TYPE II DIABETES—AN INSTRUMENTAL VARIABLE
APPROACH
Fang G1, Zuckerman IH1, Stuart B1, Brooks JM2
1University of Maryland, Baltimore, MD, USA, 2The University of Iowa,
Iowa City, IA, USA
OBJECTIVES: To study treatment outcomes (total cost, hospi-
talization, hospital stays and physician ofﬁce visits) associated
with thiazolidinedione (TZD) use among Medicare patients with
type II diabetes. METHODS: Medicare Current Beneﬁciary
Survey Cost and Use ﬁles 2000 and 2001 were used. Patient-year
approach was utilized. After applying inclusion and exclusion
criteria, patients’ sociodemographic and clinical characteristics
were characterized and compared across different treatment
groups. Instrumental variable (IV) methodology was applied
with TZD geographic area use rate as instrument and IV assump-
tions were validated. The results of IV method were compared
to that of standard ordinary least square (OLS) approach.
RESULTS: A total of 417 patients were included in the ﬁnal
analysis. More patients with actual TZD treatment had comor-
bidities >0 (69.8% vs. 56.4%, p < 0.05) and less were non-
white/black race (1% vs 7%, p < 0.05) than those without. The
TZD use rates were 17% and 29% for lower (<20%) and higher
TZD area use rate groups respectively (p < 0.01). Unadjusted
OLS models showed that actual TZD use was associated with
increased total annual cost (co-efﬁcient = 0.38, p < 0.01) and risk
of having more physician ofﬁce visits by 81%. Adjusted OLS
models showed that actual TZD use was still associated with
increased total annual cost (co-efﬁcient = 0.23, p < 0.05) and risk
of having more physician ofﬁce visits by 64% (p < 0.05). IV
approach demonstrated that higher TZD area use rate was not
associated with total annual cost, hospitalization and hospital
stays (p > 0.1). IV assumption for physician ofﬁce visits was vio-
lated as indicated by a signiﬁcant Wu-Hausman test. CON-
CLUSION: Increasing average TZD area treatment rate from
17% to 29% would not lead to increased total annual cost, hos-
pitalization and hospital stays among marginal patients in the
cohort of senior diabetic patients in this study. Future research
utilizing data with large sample size is suggested.
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HEALTH CARE EXPENDITURE AND PATIENT SATISFACTION:
COST AND QUALITY FROM HEALTH CARE CONSUMERS’
PERSPECTIVE
Fu AZ,Wang N
Cleveland Clinic, Cleveland, OH, USA
OBJECTIVES: Both cost and quality are major concerns in the
U.S. health care system. The objective of this study is to identify
the relationship between cost and quality from the health care
consumers’ perspective. METHODS: Using the 2003 Medical
Expenditure Panel Survey (MEPS), a nationally representative
sample of 13,980 adults (age ≥ 18) with their overall self-rating
of health care quality (from 0 (worst health care possible) to 
10 (best health care possible)) were included in the study. Given
the heavily right-skewed distribution of the cost data, a general-
ized linear model with log-link function was employed to iden-
tify the relationship between health care quality rating and 
total health care expenditure, after controlling for individual
demographic covariates, comorbidity proﬁle (AHRQ comorbid-
ity software), and functional and activity limitations. All sta-
tistics were adjusted using the proper sampling weight from 
the MEPS. RESULTS: The average annual health care expendi-
tures ranged between $4000 and $6000 with the mean value
$4779 for all individuals rating their received health care quality
from 0 to 10. Individuals with higher ratings for their health 
care quality did not spend more compared to individuals with
lower ratings (p = 0.72). No non-monotonic relationship 
was identiﬁed either. As one expected, comorbidities and func-
tional and activity limitations were signiﬁcant predictors of the
annual health care expenditure. An individual-level ﬁxed-effect
model using the 2003–2004 panel of the MEPS revealed the same
relationship between health care quality rating and total health
care expenditure. CONCLUSION: This study adds to the liter-
ature of health care quality by providing additional empirical evi-
dence from the health care consumers’ perspective at the U.S.
national level. Health care quality improvement, in regards to
patient satisfaction, may not require additional health care
spending.
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A METHODOLOGY FOR PROJECTING DISEASE PREVALENCE,
TREATMENT,AND EXPENDITURES FOR THE US EMPLOYER-
INSURED POPULATION
Chang S1, Hansen LG2, Marder WD3
1Thomson Medstat, Washington, DC, USA, 2Thomson Medstat,
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OBJECTIVES: This study presents a methodology to estimate
type II diabetes prevalence, treatment and costs among the ∼178
million individuals in the U.S. with employer-sponsored insur-
ance (ESI). METHODS: Estimates were made from the 2005
MarketScan® Commercial and Medicare supplemental data-
bases, which include all health care claims for approximately 
20 million employees, dependents, and retirees with ESI. The
Sample Select Prevalence tool was used to identify patients with
Type II diabetes (ICD-9-CM = 250.x0 or 250.x2) and drug treat-
ment (insulin, sulfonylurea, or other oral antidiabetic drug),
summarize annual health care expenditures, and calculate preva-
lence rates. To project these rates to the national ESI population,
weights were developed using the Household Component of the
Medical Expenditure Panel Survey (MEPS). To construct the
weights, MEPS respondents were stratiﬁed using combinations
of demographic characteristics which account for substantial dif-
ferences in utilization and expenditures. RESULTS: In the 2005
MarketScan databases, 835,048 patients with diabetes (5320
